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Background: There is a growing interest in high income countries to control expenditure on medicines by
improving the rationale for their selection. However, in middle income countries with differing priorities and needs,
little attention has been paid to this issue. In this paper we explore the policies and processes for the selection and
use of medicines in a group of hospitals in Chile, a middle income country which has recently joined the OECD.
Methods: A combination of qualitative and quantitative methods was used. A national survey questionnaire was
distributed to investigate the role and operation of PTCs (Pharmacy and Therapeutics Committees). Interviews were
conducted with key actors in the selection of medicines in large urban public hospitals.
Results: The national survey had an overall response rate of 42% (83 out of 196), whilst 7 out of 14 hospitals
participated in the qualitative study. High complexity hospitals are large urban hospitals; all of which claim to have
a working PTC. The pharmacy offices are mainly involved in dispensing medicines with little involvement in
clinical duties.
The interviews conducted suggest that the formulary of all the hospitals visited is no more than a stock list. PTCs
are unable to influence the prescribing practices of doctors. Members do not feel prepared to challenge the
opinions of specialists requesting a certain drug, and decisions are based primarily on costs. The inclusion of
medicines in the clinical practice of hospitals is as a result of doctors bypassing the PTC and requesting the
purchase of exceptional items, some of which are included in the formulary if they are widely used.
Conclusions: There is an urgent need to develop medicine policies in hospitals in Chile. The procedures used to
purchase medicines need to be revised. Central guidance for PTCs could help ensure a more rational use of
medicines. PTCs need to be empowered to design formularies which cover all the clinical needs of doctors, training
members in the analysis of scientific evidence beyond their own specialities. An influential PTC can take the
appropriate measures and design workable policies to enforce a cost effective-use of resources.Background
Expenditure on medicines is one of the largest costs in
healthcare. Consequently, countries worldwide are in-
creasingly trying to control the use of resources spent
on medicines. The World Health Organization (WHO)
recommends the use of formulary systems to improve
rationality in the use of drugs at regional, district and
local levels [1]. These formulary systems should be de-
signed and updated by multidisciplinary committees called* Correspondence: juan.collao@uv.cl
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reproduction in any medium, provided the orDrug and Therapeutics Committees (DTC) or Pharmacy
and Therapeutics Committees (PTC).
At the hospital level, the presence of these commit-
tees has been described in many high income countries,
where DTCs are considered to improve the rationality of
decisions [2-17]. Furthermore, the role of pharmacists
and the presence of pharmacy services in hospitals have
been associated with a more rational use of medicines
[18,19].
Given the differing nature of health problems faced by
rich and poor countries, there are key differences in the
objectives of hospital DTCs when selecting medicines.
On the one hand, decision-makers in low income coun-
tries need to focus on selecting medicines to save as
many lives as possible, in which case the WHO list ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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hand, committees of high income countries place em-
phasis not only on saving lives, but also on improving
the quality of life for their chronically ill patients and
promoting cost-effectiveness in prescribing, especially
regarding the use of newer drugs not listed as essential
by the WHO.
The objectives of hospital DTCs in middle income
countries are probably somewhere between those of high
and low income countries, with health needs requiring a
migration from a live-saving essential pharmacotherapy,
to one that not only saves lives, but also improves the
quality of life of their populations. Thus the way that
DTCs work in middle income countries could be dir-
ectly related to the extent to which the population can
access medicines that are not on the WHO’s essential
list.
Such is the case in Chile, an upper middle income coun-
try according to the World Bank, which joined the Or-
ganization for Economic Cooperation and Development
(OECD) in 2010. Membership of the OECD suggests that
the country will engage in the process of developing poli-
cies to improve the quality of life of its population. Never-
theless, information about Chilean hospitals is virtually
non-existent and therefore a study of decisions about me-
dicines in Chile is a good opportunity to improve our
understanding of how decisions are made in hospitals in a
middle income country engaged in the process of migra-
tion mentioned above.
The Chilean Health System
Since 1980, three health systems have coexisted in Chile;
namely, a public system serving around 70% of the po-
pulation, a private system serving approximately 27%,
and the health system for the armed forces for around
3% of Chilean citizens [20]. The most important provi-
der of secondary care is the public network of hospitals
which covers most towns and cities in Chile; while large
highly complex private hospitals are only found in the
biggest cities. Public hospitals are classified by the Min-
istry of Health as high and low complexity hospitals.
There are no official criteria for classifying hospitals as
high or low complexity according to defined parameters.
Instead, the classification seems to be based on how the
network operates: low complexity hospitals aim to im-
prove geographical coverage, while high complexity hos-
pitals are regional or reference centres to which low
complexity hospitals refer patients who require a more
complex level of care.
The health reform
A health reform was in progress at the time of the
research, which aimed to ensure coverage for a list of
catastrophic diseases by progressively implementing aprogramme called GES (meaning Explicit Guarantees in
Health). In this programme, both private and public insur-
ance systems are required to fully cover all costs in the
treatment of a defined list of 69 diseases (at no cost to the
patient), such as different types of cancer, HIV, diabetes
and cystic fibrosis. The treatment of these diseases must
be in accordance with clinical guidelines designed by a
panel of experts.Pharmaceutical policies in Chile
For a medicine to be commercialized in Chile, the manu-
facturer needs to register their product with the National
Institute for Health (ISP). The ISP is not a specialised
medicines agency, but the agency in charge of overseeing
the safety of every product that is consumed by humans
and animals. At the time of the study, generic medicines
were only required to present clinical studies performed
for the original drug. Currently the ISP is implementing a
National Agency for Medicines (ANAMED) and generic
drugs will be required to prove bioequivalence in order to
be granted market authorization in Chile.
Chile has a long tradition of pharmaceutical policies.
In fact, the first National Formulary of Medicines was
developed in Chile between 1965 and 1970, and later
adopted by the WHO in 1977 [21]. Unfortunately, bet-
ween 1973 and 2004 no pharmaceutical policies were in
force, with the commercialization and use of medicines
regulated almost exclusively by market laws. Currently,
the National Formulary of Medicines is simply a list of
medicines that have been granted market authorization
in Chile and does not include any treatment guidelines
for those drugs.
The National Medicines Policy published in 2004
(i.e. 4 years before the study) establishes that all hos-
pitals, regardless of their complexity, must have a Phar-
macy and Therapeutics Committee in charge of decisions
about medicines. The PTC should be chaired by the med-
ical director, the secretary of the committee should be the
head of the Pharmacy Department, and all clinical depart-
ment heads should be permanent members.
This study explores the policies and processes involved
in the use of medicines in Chilean public hospitals and
aims to explore the extent to which decisions concern-
ing the formulary of medicines are rational, and how
these decisions could be improved. Moreover, the study
may also help decision makers to develop policies and
procedures for the selection and use of medicines in
other middle income countries.Research questions
1. What are the characteristics of Chilean Public
hospitals in terms of the number of beds, the duties
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the existence of multidisciplinary committees?
2. What are the central and local policies and
procedures for the selection of medicines in Chilean
public hospitals?
3. What are the formal and informal ways by which the
use of a drug not previously used is commenced in
Chilean public hospitals?Methods
Due to the virtual absence of published information
about Chilean public hospitals, a combination of quanti-
tative and qualitative methods was used to address these
questions. A two-stage study was performed, comprising
a survey followed by semi-structured interviews with
purposively selected informants. By using these comple-
mentary methods it was possible to gather structured
data concerning the aspects of Chilean hospitals that are
described in the literature as factors that influence the
innovativeness of institutions [8,10,22,23], and it was
also possible to explore relevant issues and processes in
context.Nationwide survey
Overview
A postal survey was designed in order to identify charac-
teristics of Chilean Public hospitals. The questionnaire
requested information on hospital size, complexity, and
the existence of a PTC [8,10,22-28] (Additional file 1).Sampling strategy and procedure The survey was a
population study, with the questionnaire sent to all 196
hospitals that appear on the Ministry of Health’s website.Development of instruments The first draft of the ques-
tionnaire was piloted with five hospital pharmacists, se-
lected using a snowballing technique following initial
contact with a hospital pharmacist previously known to
a member of the research team. After corrections were
made, the second draft was piloted and discussed with a
further snowball sample of hospital pharmacists until no
new issues emerged.Data collection In January 2008, the questionnaire with
an explanatory letter from the research team, a letter
from the Ministry of Health encouraging response, and
pre-paid envelopes to return the questionnaire, were sent
to all hospitals addressed to “The person in charge of the
pharmacy office”. After two months, a second question-
naire was sent to non-respondents with a personalised let-
ter encouraging response to the questionnaire.Data processing and analysis The responses to the
questionnaire were entered and analysed using SPSS 18W
software and descriptive procedures.
Ethics statement The survey requested information
about the hospital and did not include any questions
which could involve patient data. The survey was then
submitted to the Chilean Ministry of Health for ethics
approval which was deemed unnecessary.
Qualitative study
Overview
The results of the questionnaire suggest that high com-
plexity hospitals are more likely than low complexity
hospitals to innovate in their pharmacotherapy, and hence
be more likely to deal with new medicines. Therefore, we
conducted a qualitative study in high complexity hospitals
in order to answer research questions 2 and 3. From May
2008 to August 2008, interviews were carried out with the
chief of the Department of Pharmaceutical Policy at the
Ministry of Health, members of PTCs, doctors who had
applied for new medicines to be added to the formulary,
nurses, and clinicians working in the hospital (Additional
file 1).
Sampling strategy, procedure and recruitment Dif-
ferent sampling strategies were used for the selection of
cities, hospitals and interviewees inside hospitals. Firstly,
for practical purposes only three cities could be selected
for the study. The cities were: Santiago, the capital city
located in the geographical centre of the country with
approximately 6 million inhabitants; Valparaíso located
on the coast 150 km from Santiago with a population of
nearly one million; and Coquimbo, 450 km north of
Santiago with less than half a million inhabitants. Thus,
these urban hospitals represent different regions of the
country where specialist doctors tend to be concentra-
ted. Secondly, fourteen hospitals in these cities were se-
lected using purposive sampling aiming to include at
least one of the different types of high complexity hospi-
tals present in those selected cities (i.e. child, cancer,
psychiatric, and general hospitals). Thirdly, a snowbal-
ling strategy was employed to select hospital staff, start-
ing with the chief pharmacists who then identified other
members of the PTC. Doctors who had applied for a
drug to be admitted to the formulary were identified
from the minutes of PTC meetings. The last two doctors
who had applied for a drug were contacted through the
chief pharmacist.
Clinicians were identified by convenience sampling, in
which the researcher approached the first doctor found
after walking into the wards and asking them to parti-
cipate in the project (all wards of the hospital were
included). Interviews with doctors were continued until
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ging), or in the cases of two hospitals (where recruiting
doctors was difficult) until the planned visiting time for
the hospital was over.
Development of instruments Specific interview sche-
dules were designed for pharmacists, members of the
PTC, drug applicants, clinicians and nurses. The inter-
view schedules included open questions about national
and local policies regarding the use of medicines, formal
and informal procedures for using medicines not inclu-
ded in the formulary, the purchase of medicines, and
about how the pharmacy office oversees the use of medi-
cines in the hospital.
Data collection The interviews were carried out bet-
ween April and July 2008 by a Chilean pharmacist and
researcher with no previous working experience in hos-
pital pharmacy in Chile, hence with no prejudgement
about the possible answers to the interviews. The inter-
viewer, trained in relevant research methods, maintained
the principles of the qualitative enquiry while perfor-
ming the interviews, limiting himself to encouraging
interviewees to give more information about topics that
emerged during interviews. Interviews were audio recor-
ded with the consent of the interviewee; when permis-
sion was not granted, written notes were taken.
Minutes of PTC’s meetings held during the year 2007
were reviewed to identify medicines that had been in-
cluded in the formulary during that year.
Data processing and analysis Recorded interviews were
transcribed verbatim and then analysed in their original
language using the MAXQDAW qualitative analysis soft-
ware. The analysis was carried out using a thematic ap-
proach identifying policies and procedures relating to
the inclusion of drugs in the clinical practice of the hos-
pitals. Subsequently, policies were sub classified into na-
tional and local policies, and procedures into formal and
informal procedures. The analysis was carried out using
an approach based on the Grounded Theory, coding
the data into different hierarchies as suggested by the
data itself. These hierarchies were the result of an it-
erative process in which accounts were classified intoTable 1 Summary of characteristics of Chilean hospitals
High complexity hospitals
N Min Max
Number of beds 28 116 720
Number of clinical units 27 4 25
Pharmacists per 100 beds 27 0.47 2.47
Expenditure per bed/year 2007 (US$) 26 1478 2689the different codes and then re-classified into sub-codes
until no further issues emerged.
Ethics statement The interview schedules did not
contain any questions involving individual patient’s data.
Nevertheless, we submitted the questions to the Ethics
Committee of one of the participant hospitals; this com-
mittee established that no ethics approval was necessary
for the study.
Results
Nationwide survey
Characteristics of samples and response rates
83 hospitals responded to our questionnaire, represent-
ing 48% of all high complexity hospitals and 40% of low
complexity hospitals (42% overall). Geographically, the
survey obtained responses from 14 out of the 15 admin-
istrative regions of the country, which represents a good
picture of the different realities of public hospitals in
Chile.
Chilean public hospitals
Respondent hospitals ranged from basic undifferentiated
rural facilities with as few as six beds, to urban hospitals
with a maximum of 720 beds. All the high complexity
hospitals are located in urban areas (i.e. more than
10,000 inhabitants), and 54% of the low complexity hos-
pitals are in urban areas. Table 1 summarizes the find-
ings of the national survey regarding the characteristics
of Chilean hospitals.
The hospital pharmacies
A pharmacist is in charge of the pharmacy office in all
but one high complexity hospital. Conversely, only 48%
of low complexity hospitals have a pharmacist in charge.
On average, high complexity hospitals have 3.9 pharma-
cists (full-time equivalents) per hospital, while low com-
plexity hospitals have 0.5. Moreover, the number of
pharmacists per 100 beds is 1.16 for high complexity
and 0.75 for low complexity hospitals.
The pharmacy offices are found to be concerned main-
ly with the dispensing of medicines and medical supplies,
with the manufacturing of extemporaneous medicines,
and the preparation of parenteral nutrition. Pharmacists
are mostly involved in administrative work, although onLow complexity hospitals
Mean N Min Max Mean
340.6 51 6 317 63.8
10.5 53 0 9 3.6
1.16 51 0 3.33 0.75
1 6815 46 121 17928 2915
Table 2 Composition of PTCs in Chilean public hospitals
Complexity
level
Doctors Pharmacists Nurses/midwives Dentists Commercial/
administrative professionals
Other
professionals
No degree
High 100% (28/28) 100% (28/28) 82% (23/28) 18% (5/28) 60% (17/28) 14% (4/28) 0% (0/28)
Low 100% (45/45) 56% (25/45) 84% (38/45) 44% (20/45) 33% (15/45) 22% (10/45) 53% (24/45)
Total 100% (73/73) 73% (53/73) 84% (61/73) 34% (25/73) 30% (22/73) 19% (14/73) 33% (24/73)
The figures represent the percentage of PTCs having one or more permanent members with the indicated profession.
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ical duties such as monitoring the use of antibiotics and
therapies in critical care units.
Pharmacy and Therapeutics Committees
According to the survey, all the high complexity hospi-
tals and 89% of the low complexity hospitals have a
PTC. In terms of how long these committees have been
established, 83% of high complexity hospitals have a
committee actively working for 5 or more years, while
only 39% of low complexity hospitals have a committee
that has been working for five or more years. The pro-
fessions of those working in the PTCs of hospitals that
responded to the national survey are summarized in
Table 2. Additionally, the frequency of meetings agreed
by PTCs and the reported number of drug applications
discussed in a typical PTC meeting are shown in Tables 3
and 4 respectively.
Drug expenditure
The annual expenditure on medicines in Chilean hospi-
tals was estimated based on the responses to the survey
and expressed as expenditure per bed. For high com-
plexity hospitals the average expenditure per bed was US
$6,815 during the year 2007, while for low complexity
hospitals the average was US$2,914. The overall expend-
iture per bed was US$4,233.
Qualitative study
Response rates
Only seven out of the 14 hospitals originally invited,
agreed to participate in the study; namely, three regional
hospitals, one cancer hospital, one children’s hospital
and two general hospitals in the capital city. Altogether,
the head of the Department of Pharmaceutical Policies at
the Ministry of Health, seven pharmacists, nine membersTable 3 Agreed frequency of meetings of PTCs
High complexity hospitals
Frequency of agreed meetings N Percentage (va
Bi-monthly 5 17.2
Monthly 12 41.4
Quarterly 10 34.5
Bi-annually 1 3.4
Other 1 3.4of PTCs, six applicants for drugs, five nurses and 41 clini-
cians were interviewed.
Medicines budget
The budget for medicines was calculated according to
the historical expenditure plus an additional 6 to 7%
of annual growth. Although some pharmacists reported
that the budget has increased as a result of the GES
programme, all of them agreed that the budget is insuf-
ficient as hospitals are facing an uncontrolled increase
in debt.
Policies on the selection of medicines
Pharmacy and Therapeutics Committee At the time
of the study, hospitals were periodically audited to find
out if they had a PTC by the Sub-secretariat of Health
Network of the Ministry of Health. Nevertheless, no
evaluation into how these committees actually function
was undertaken at the time. Indeed, pharmacists and
members of the committee seemed to only be aware that
there is an obligation to have a PTC through those au-
dits rather than through the Department of Pharmaceu-
tical Policies.
All of the hospitals visited during the study have a
working PTC that has been functioning for at least five
years. These hospitals use a form stating the generic name,
the number of potential patients, and the scientific evi-
dence, as recommended by the national policy.
The formulary Every hospital is required to have a list
of the medicines that are used to treat patients, which
translated literally into English would be called a “Thera-
peutic Arsenal”. If a medicine is on the list, the hospital
is obliged by law to have a permanent stock of it and
could be sued by a patient if a doctor prescribes the drugLow complexity hospitals
lid responses) N Percentage (valid responses)
2 4.3
8 17.0
22 46.8
12 25.5
3 6.4
Table 4 Reported number of drug applications discussed in a typical meeting of the PTC
High complexity hospitals Low complexity hospitals
Number of drug applications discussed per meeting Frequency Percentage (valid responses) Frequency Percentage (valid responses)
No application discussed yet 0 0 5 10.6
One or less 10 35.7 14 29.8
Two or three 13 46.5 18 38.3
Four or five 3 10.7 6 12.8
More than five 2 7.1 4 8.5
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ing to pharmacists this information is not common
knowledge and patients are not normally informed of
this legal requirement. In addition to GES guidelines,
only one of the seven participant hospitals had designed
clinical guidelines for the treatment of their patients, but
these guidelines were written by each clinical depart-
ment and not by the PTC. Interviewees admitted that
these guidelines are seldom used.
The GES programme There is a different policy for
medicines that are included in the GES programme.
The clinical guidelines for each disease included in the
programme recommend specific treatments to hospitals;
however, the paying party (FONASA in the case of pub-
licly insured patients) only reimburse medicines that are
mentioned in the clinical guidelines, making the inclu-
sion of these medicines in the formulary mandatory.
Formal Practices relating to the use of medicines
The Pharmacy and Therapeutics committee The se-
lection of medicines in the hospitals we visited is carried
out, according to our interviewees, by a multidisciplinary
committee referred to as the Pharmacy and Therapeutics
Committee. Invariably, the chair of this committee is the
hospital director and the secretary is the chief pharma-
cist. The heads of the various clinical departments are
permanent members of the committee, with the excep-
tion of one hospital where the committee is formed by
the chair, the secretary, a clinical pharmacologist and the
head nurse.
“. . . we used to include all the heads of the clinical
departments, but they were on the committee only
to ask for medicines, they didn’t really contribute
to the debate. . .” (Chief pharmacist)
The application process There was no consensus as to
who is authorised to apply for medicines to be added to
the formulary, some interviewees said that only doctors
are authorised, while others said that any health profes-
sional can apply. This lack of consensus was generalised,
with statements for both sides made in all hospitals. Tomake an application, applicants are required to fill in the
form, submit it to the head of the clinical department
for authorisation (signature) and submit it to the phar-
macy office. In terms of the types of evidence that are
usually submitted with the application form, the consen-
sus is that applicants do not provide sufficient evidence
to support the application.
“. . . well, I can’t lie to you, the evidence is normally
weak, very weak. . .” (Member of the PTC)
Moreover, some pharmacists claimed that in certain
cases doctors support their applications by writing the
phrase “because I need it” on the form.
In two of the hospitals the committee’s secretary is re-
sponsible for providing the evidence to support the ap-
plication. We asked applicants and pharmacists about
the source of the information that is usually presented
to the committee; the most common answer was “scien-
tific publications” but without naming any specific publi-
cation. Only one applicant mentioned databases such as
the Cochrane Collaboration and Web of Knowledge.
Interestingly, all applicants and pharmacists mentioned
the drug company’s representative as a source of scien-
tific articles.
“. . . and representatives, they always bring papers,
they are very useful. . .” (Chief pharmacist)
The decision-making process In all the visited hospi-
tals, after the application is received by the committee’s
secretary, the application is put on the next meeting’s
agenda to be presented to the members. In the subse-
quent meeting, its inclusion on the TA is discussed, once
members have had the chance to study the application.
During the meeting where the application is discussed,
the application is sometimes presented by the applicant
and sometimes by the secretary of the committee. Fol-
lowing a discussion of the evidence submitted, a decision
is reached by consensus. In one of the hospitals, inter-
viewees mentioned the use of a formula to weigh the dif-
ferent aspects of the application such as cost, number of
patients to be treated and the drug’s cost-effectiveness
ratio.
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sion, all the interviewees agreed that it is mainly centred
on costs; in particular, members of the PTC pointed out
that when the drug in question is out with their special-
ity, they do not feel they can contribute an authoritative
opinion to the discussion, hence the focus on costs.
Perceptions of the PTC The opinion of the PTC among
members of the committee is very positive. They high-
lighted that the existence of the committee adds formality
and transparency to the process of selecting medicines.
However, the opinion of clinicians is less clear; when
asked about the local policy to incorporate a drug into the
TA, only 16 out of the 41 interviewed doctors were aware
of a local policy involving a PTC. Out of the 16 doctors
who were familiar with the policy, only seven could name
the functions of the PTC. In addition, all of the doctors
who were unaware of the policy thought that the policy
for including a medicine in the TA was to “ask for it in the
pharmacy”.
In addition, there was some criticism as to how the
PTC works, with doctors mainly criticising the bureau-
cracy of the system; while pharmacists complained about
the extra work load that the committee entails for them,
as well as the slowness of the process.
The exceptional purchase procedure In parallel to the
formal application process for medicines not included
in the TA, hospitals have a formal procedure through
which doctors can request the purchase of a medicine
not included in the TA. Doctors need to fill in a form
requesting the drug and explaining their reasons for the
request and submit the form to the pharmacy office.
This request is then sent to the medical sub-director
who decides whether or not the pharmacy office will buy
it. According to doctors and pharmacists, the entire pro-
cedure takes just one day or less for the doctor to obtain
the requested drug. All chief pharmacists agreed that
this procedure is overused by doctors, and recognised
that medical sub-directors rarely reject an application
for exceptional purchases.
“. . . we had eight applications for drugs last year
(2007). . . For exceptional purchase? Well more
than 2,000. . . way more. . . I just can’t count them”
(Chief pharmacist)
Moreover, the number of requests for some medicines
has grown steadily over time, overtly becoming part of
the medicines normally used in the clinical practice of
the hospital without approval by the committee, even
though chief pharmacists are not keen to include them
in the Therapeutic Arsenal because they create an eco-
nomic burden for the hospital.“. . . For me it’s also easier to buy medicines through
the exceptional purchase, they are normally more
expensive drugs and if we include them in the TA
everybody will start prescribing them. . . the
hospital can’t afford that. . .” (Chief pharmacist)
It is important to point out that this is the result of
the PTC including medicines in the formulary but with-
out any restrictions on their use. Once a new medicine
is on the TA, any doctor can prescribe it.
Moreover, due to the extra work load involved in pro-
cessing many requests for a particular drug, in all the
visited hospitals the committee decided to formally in-
clude the medicine in the formulary without a formal
application for the drug, or by asking doctors to submit
a formal application. In these cases the drug is included
without a discussion of the evidence on the use of the
drug. Some doctors and nurses raised the issue of the
limited scope of medicines used in public hospitals,
which in their opinion leaves them no alternative but to
request the appropriate drug using the exceptional pur-
chase protocol.
“. . . the Therapeutic Arsenal of public hospitals is
really limited, there are only basic drugs outdated
long ago . . .” (H1.21 Clin 1)
Informal practices relating to the use of medicines
The private purchase of medicines The most common
informal practice mentioned by physicians in the hospi-
tals in this study, is the external purchase of drugs. In
this practice, the doctor issues a prescription for the pa-
tient or his/her relatives to buy one or more medicines
in a community pharmacy, for use in the hospital. Even
though this practice implies an agreement between doc-
tor and patient, there was no mention of any informed
consent.
It is not clear how common this practice is, since dif-
ferent kinds of interviewees had different opinions on
the subject. On the one hand, 27 out of the 41 physi-
cians interviewed in hospitals mentioned this practice as
a common way for them to prescribe drugs not listed in
the formulary. On the other hand, pharmacists and PTC
members insisted it is rare.
Nurses reported perceived frequencies of private pur-
chases ranging from none to 20% of all prescriptions in
their wards. Moreover, nurses pointed out that private
purchases are usually for one of three reasons; namely,
specific drugs not included in the TA, a temporary stock
shortage of the drug in the hospital, and doctors simply
wanting to prescribe drugs of “better quality than those
used by the hospital”. Furthermore, in four cases, the
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not patients receive private prescriptions, is if the doctor
thinks the patient can afford to buy the drug or not (see
Figure 1).
The use of free prescription samples Similarly, the use
of free samples to treat patients in hospitals was fre-
quently mentioned in the interviews by clinicians and
nurses, but pharmacists seem to be unaware of the use
of free samples to treat patients. Doctors gather medical
samples, probably from drug representatives visiting the
hospital, and treat patients that cannot afford to pay for
the medicines themselves with samples provided by phar-
maceutical companies. Nevertheless, it was not possible to
establish whether this is common practice from the inter-
views. In one of the visited hospitals, we frequently ob-
served representatives of pharmaceutical companies in the
hospital corridors giving doctors promotional plastic bags
with unknown contents.
Discussion
This study presents, for the first time, information on
both the size and the complexity of Chilean hospitals
and the control of medicines within them. The results of
the qualitative study are, to the best of our knowledge,
the first attempt to widen our knowledge on how de-
cisions about medicines are made in public hospitals
of a middle income country like Chile. Nevertheless,
conducting research in a health system where people
are not used to research was not without problems; aFigure 1 Routes to include a drug in the clinical practice of Chilean p
drug not included in the formulary of Chilean hospitals. (1) Doctors can ap
request the exceptional purchase of a medicine. (3) If they think the patien
be used in the hospital. The number of requests for exceptional purchases
associated with processing too many requests, the pharmacy office asks thmarked resistance of individuals to participate was ob-
served during the fieldwork. Although the study does not
identify the reasons for this resistance, we believe that in-
cluding qualitative methods in the design is particularly
appropriate to answer our research questions, instead of a
questionnaire providing limited perspectives.
Despite this, we think that some biases could be pre-
sent in the results of the qualitative study. Indeed, only
seven out of the 14 hospitals agreed to participate in the
qualitative study, with pharmacists of those hospitals
expressing a high opinion of their PTCs. High complex-
ity hospitals that responded to the questionnaire account
for almost half the total number of those hospitals, which
raises the question of whether the absence of a working
PTC might be the reason for some hospitals not respond-
ing. Thus, there is a possibility that hospitals with less ac-
tive PTCs could be underrepresented in this study.Policies
The national policy for the use of a PTC is clear and
acknowledged by hospitals. Nevertheless, it seems that
the policy is often viewed by hospitals as an obligation
imposed on them as part of the administrative changes
currently taking place in the public sector, rather than a
useful tool to improve the rationality of decisions. In the
local context, policies on the use of drugs are not pre-
sent or not enforced in practice, with an absence of clin-
ical guidelines to support doctors’ decisions to prescribe
medicines included in the formulary. In fact, with theublic hospitals.Three routes are available for doctors to prescribe a
ply to the PTC for a drug through the pharmacy office. (2) They can
t can afford the drug, they can ask them to buy the drug privately to
grew gradually over time for some drugs; to avoid the paperwork
e PTC for the inclusion of this drug into the formulary (4).
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tions were identified.
The formulary
The formulary used in Chilean hospitals seems to be no
more than a stock list. According to our results, the so
called Therapeutic Arsenal does not include clinical
guidelines to orientate doctors in the use of medicines
within hospitals. Moreover, the obligation to keep a per-
manent stock of the medicines that appear in the TA
might be discouraging hospitals from updating their
TAs, but this could be overcome by including medicines
along with appropriate policies for their use. In addition,
it is also possible that Therapeutics Arsenals do not
cover the whole spectrum of medicines needed to treat
patients in those hospitals, obliging doctors to seek med-
icines outside the hospital.
Even when the reasons for prescribing medicines that
are not included in the Therapeutic Arsenal are unclear,
the lack of obligation to prove the bioequivalence of
generic medicines in Chile may be relevant. With hospi-
tals using mostly generic drugs, the distrust doctors
show towards these types of drugs is an important issue
that can partially explain why doctors prescribe drugs
not included in the TA of public hospitals.
Additionally, PTCs in Chile need to develop formulary
systems which can effectively cover all the pharmaco-
therapy needed in hospitals, avoiding the exceptional
purchase of medicines. Moreover, it is necessary to im-
prove our understanding of doctors’ reasons for prescri-
bing medicines that are not included in the TherapeuticPTC
Selec
Acquisition
Prescription
Dispen
Pha
Figure 2 Information-flow diagram. Instead of a linear process, the use o
information on each stage of the use of medicines is shared by the PTC, th
about the use of medicines included in the Therapeutic Arsenal.Arsenal; taking the appropriate measures to avoid this
practice will result in a more rational use of medicines.
Moreover, it is important to improve the communica-
tion between the PTC, clinicians and the pharmacy
office. At the time of the study, the use of medicines
appeared to be a linear process in which medicines were
selected, prescribed, dispensed, and then administered;
but there was no feedback about the outcomes achieved
with newly included medicines. Thus, to achieve a more
rational use, there should be continuous communication
between the PTC, the Pharmacy office and clinicians
about the use of drugs (see Figure 2).
The Pharmacy and Therapeutics Committee
Jenkings and Barber describe the lack of skills of DTC
members to analyse and contextualise scientific informa-
tion [29]. Coincidentally, members of the studied PTCs
self-reported that the evidence discussed in PTC ses-
sions is often difficult to apply to the Chilean reality, and
they do not feel able to challenge the opinions of specia-
lists in areas other than their own. This is clearly a bar-
rier to making more rational decisions in Chilean
committees, highlighting the need to train members in
the appraisal and analysis of scientific information be-
yond the scope of their specialities.
There is a positive perception among members of the
PTC about having a committee in charge of decisions to
include a drug in the TA. However, it seems that for the
group of hospitals under study, the PTC does not have
enough authority to influence prescribing in their own
hospitals, leaving innovation in the use of drugs (i.e. usingtion
sation
Administration
Outcomes
rmacy
f medicines in Chilean hospitals should be continuous where
e pharmacy office and clinical services, providing continuous feedback
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individual doctors or groups of doctors. This lack of au-
thority could be the result of poor argumentation about
reasons to include or not a medicine in the formulary and
the lack of communication about the decisions of health
professionals working in the hospital, undermining the le-
gitimacy of the committee’s decisions.
This need for legitimacy can be improved with an ethi-
cal approach called the ‘Accountability for Reasonable-
ness [30]; this approach was put forward to give greater
legitimacy to health technology decisions. This approach
advises that decisions must be effectively communicated
to doctors, stating the rationale for the decision and gi-
ving the opportunity to appeal. By using an ethical ap-
proach such as the Accountability for Reasonableness,
decisions made by the PTC can gain greater legitimacy,
gradually building the authority needed to influence pre-
scribing in the group of hospitals included in this study.
Moreover, several authors suggest different strategies
to improve the decision-making process for including a
drug in the formulary. In this respect, Tan et al. suggest
that institutions should clearly state a hierarchy of prior-
ities before any discussion on including a drug is made
[31], and Schiff et al., propose a Formulary Drug Appli-
cation Tool, which they suggest might help DTC mem-
bers to evaluate claims about drugs made during the
application process, giving a framework to improve the
level of the discussion [32].
The GES programme
Medicines included in the GES programme are normally
drugs not included in the TA of the hospitals under
study; in practice, they are imposed on hospitals, contra-
dicting what the National Policy of Medicines of 2004
states regarding the selection of medicines. Nevertheless,
since decisions to include a drug into the TA are normally
based almost exclusively on costs, it is highly probable that
hospitals would not include those drugs in their TAs if
they were not obliged to. Thus, the obligation of hospitals
to include GES drugs could be improving the access to
more innovative medicines in those hospitals.
Conclusions
The national policy for selecting medicines in public
hospitals is, as recommended by the WHO, through lo-
cal multidisciplinary committees; however, there is a
need to improve the ability of committees to influence
prescribing towards evidence based practice. More cen-
tral guidance on the selection of new medicines could
help committees to make more rational decisions, and
to design policies and protocols for the use of medicines
based on the best available evidence.
There is also a need to revise the mechanisms for pur-
chasing medicines in public hospitals to improve theirquality and to circumvent abuses of the exceptional pur-
chasing system. In general, the lack of regulation in the
Chilean market for medicines may be having a negative
impact on the access to good quality medicines for the
majority of Chilean citizens.
More research is needed to better understand how me-
dicines are used in Chilean hospitals; for instance, it is
fundamental to establish doctors’ reasons for prescribing
medicines that are not included in the formulary. Only by
understanding how medicines are used in Chilean hos-
pitals, can the appropriate policies be put in place to im-
prove rationality in the use of medicines.
The results of this study can serve as a basis for further
research into how middle income countries can change
their priorities, means and needs in terms of healthcare
and the way medicines are used. Such research can be
used to develop appropriate policies for an optimal use of
medicines and to improve health outcomes.
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